Agenus Stock Forecast for 2023 - 2025 - 2030
Updated on 04/26/2024
Agenus Stock Forecast and Price Target
The average target price for Agenus's stock set by two renowned analysts in recent months is $80.00, representing a potential upside of approximately 863.86% from its last closing price if met by 2025. This estimation is based on a high estimate of $160.00 and a low estimate of $35.00. If you are not interested in AGEN stock, you may be interested in its competitors.
863.86% Upside
Agenus Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Agenus's Price has grown by 100.00%, rising from $0.00 to $0.00. For next year, analysts predict Fair Value of $8.93, which would mean an increase of 100.00%. Over the next seven years, experts predict that Agenus's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$724.87 | Buy/Sell | $636.99 | 15.54% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$146.82 | Buy/Sell | $174.55 | 15.79% |
| MRK Stock Forecast | Merck | Outperform |
2
|
$130.72 | Buy/Sell | $130.51 | 7.10% |
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$25.26 | Buy/Sell | $32.87 | 20.74% |
| VRTX Stock Forecast | Vertex Pharmaceuticals Inc | Outperform |
12
|
$397.70 | Buy/Sell | $457.59 | 13.15% |
Agenus Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Agenus's Revenue has grown by 11.17%, rising from $88.17M to $98.02M. For next year, analysts predict Revenue of $197.47M, which would mean an increase of 101.46%. Over the next seven years, experts predict that Agenus's Revenue will grow at a rate of 818.92%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$44.70 | Buy/Sell | $58.15 | 21.92% |
| REGN Stock Forecast | Regeneron Pharmaceuticals | Outperform |
2
|
$890.68 | Buy/Sell | $961.26 | 17.89% |
| ZTS Stock Forecast | Zoetis | Outperform |
18
|
$153.36 | Buy/Sell | $220.47 | 44.11% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$40.23 | Buy/Sell | $44.86 | 11.86% |
| ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$143.71 | Buy/Sell | $245.24 | 49.61% |
| VTRS Stock Forecast | Viatris Inc | Hold |
8
|
$11.47 | Buy/Sell | $11.73 | 4.62% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| UTHR Stock Forecast | United Therapeutics | Outperform |
12
|
$235.95 | Buy/Sell | $284.08 | 25.87% |
| CTLT Stock Forecast | Catalent | Hold |
15
|
$55.80 | Buy/Sell | $49.29 | 13.80% |
| CYTK Stock Forecast | Cytokinetics | Outperform |
10
|
$64.80 | Buy/Sell | $87.92 | 45.06% |
Agenus EBITDA Forecast for 2023 - 2025 - 2030
Agenus's EBITDA has seen impressive growth In the last two years, rising from $-108.84M to $-173.30M – a growth of 59.22%. According to 0 analysts, Agenus's EBITDA will fall by 32.15% in the next year, reaching $-117.58M. Professionals believe that By 2030, Agenus's EBITDA will fall to $-129.76M – a 25.13% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IONS Stock Forecast | Ionis Pharmaceuticals | Outperform |
9
|
$41.84 | Buy/Sell | $55.60 | 43.88% |
| MDGL Stock Forecast | Madrigal Pharmaceuticals | Outperform |
4
|
$194.38 | Buy/Sell | $315.92 | 100.64% |
| BCPC Stock Forecast | Balchem | Outperform |
18
|
$138.50 | Buy/Sell | $145.00 | 15.16% |
Agenus EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Agenus's EBIT has grown by 55.37%, rising from $-116.01M to $-180.24M. In the following year, 5 experts forecast that Agenus's EBIT will decrease by 52.29%, to $-85.99M. In 2030, professionals predict that Agenus's EBIT will decrease by 308.00%, to $374.90M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PRGO Stock Forecast | Perrigo Co PLC | Outperform |
16
|
$31.27 | Buy/Sell | $44.75 | 26.64% |
| NEOG Stock Forecast | Neogen | Outperform |
16
|
$11.96 | Buy/Sell | $37.00 | 42.14% |
| INDV Stock Forecast | Indivior PLC | Buy |
14
|
£14.00 | Buy/Sell | £28.89 | 123.14% |
Agenus EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Agenus's EPS has grown by 100.00%, rising from $-1.05 to $0.00. For next year, analysts predict EPS of $-0.41, which would mean an increase of 100.00%. Over the next seven years, experts predict that Agenus's EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CORT Stock Forecast | Corcept Therapeutics | Buy |
16
|
$22.21 | Buy/Sell | $35.67 | 71.09% |
| IRWD Stock Forecast | Ironwood Pharmaceuticals | Buy |
14
|
$8.08 | Buy/Sell | $17.83 | 110.40% |
| TGTX Stock Forecast | TG Therapeutics | Outperform |
9
|
$13.91 | Buy/Sell | $29.44 | 144.43% |
.jpg)